M&A - Bruhlmann Christian

Form Type: SCHEDULE 13D/A

Filing Date: 2025-02-14

Corporate Action: Acquisition

Type: Update

Accession Number: 000121390025014284

Filing Summary: This Amendment No. 1 relates to Christian Bruhlmann's acquisition of shares in Onconetix, Inc. The document updates the original Schedule 13D filed on October 1, 2024, and highlights that Bruhlmann, as an officer of the Issuer, beneficially acquired 433,910 shares and additional shares issuable upon settlement of Restricted Stock Units (RSUs). The acquisition stems from the Share Exchange Agreement dated December 15, 2023, whereby Onconetix, Inc. acquired all equity interests of Proteomedix AG, leading to a rebranding of the combined entity. Following the acquisition, Bruhlmann received 236,029 shares and 171,204 shares of Series B Convertible Preferred Stock, which were converted into common stock, totaling 428,010 shares post a reverse split executed on September 24, 2024. The document further states that Bruhlmann received an additional grant of 177,462 fully vested RSUs on December 20, 2024. He ceased to be a beneficial holder of more than five percent of the Issuer's Common Stock as of December 31, 2024. The Lock-Up Agreement specifies terms regarding the handling of acquired shares until the end of December 2024.

Document Link: View Document